PLoS ONE · 2022 · 14 citations · 55 references
PharmacyHealth PolicyPharmacoeconomicsCost-effectiveness AnalysisHealth Policy AnalysisPharmacoeconomic ModelingCost-effectiveness ModelingEconomic EvaluationHealthcare Cost AnalysisModel-based Economic EvaluationPharmacoeconomic EvaluationWillingness-to-pay ThresholdsCardiovascular Disease PolicyCost-effectivenessCost-effectiveness Analysis PerspectiveDisability-adjusted Life ExpectancyDisability-adjusted Life Year AnalysisDisability-adjusted Life YearsMethods Of Economic EvaluationSocietal Perspective Analysis
INTRODUCTION: There is inadequate information on the cost-effectiveness of hypertension based on evidence-based guidelines. Therefore, this study was conducted to evaluate the cost-effectiveness of hypertension treatment based on 2020 International Society of Hypertension (ISH) guidelines from a societal perspective. METHODS: We developed a state-transition Markov model based on the cardiovascular disease policy model adapted to the Sub-Saharan African perspective to simulate costs of treated and untreated hypertension and disability-adjusted life-years (DALYs) averted by treating previously untreated adults above 30 years from a societal perspective for a lifetime. RESULTS: The full implementation of the ISH 2020 hypertension guidelines can prevent approximately 22,348.66 total productive life-year losses annually. The incremental net monetary benefit of treating hypertension based was $128,520,077.61 US by considering a willingness-to-pay threshold of $50,000 US per DALY averted. The incremental cost-effectiveness ratio (ICER) of treating hypertension when compared with null was $1,125.44 US per DALY averted. Treating hypertension among adults aged 40-64 years was very cost-effective 625.27 USD per DALY averted. Treating hypertensive adults aged 40-64 years with diabetes and CKD is very cost-effective in both women and men (i.e., 559.48 USD and 905.40 USD/DALY averted respectively). CONCLUSION: The implementation of the ISH 2020 guidelines among hypertensive adults in Southern Ethiopia could result in $9,574,118.47 US economic savings. Controlling hypertension in all patients with or with diabetes and or CKD could be effective and cost-saving. Therefore, improving treatment coverage, blood pressure control rate, and adherence to treatment by involving all relevant stakeholders is critical to saving scarce health resources.
55
Gregory A. Roth, Degu Abate, Kalkidan Hassen Abate et al. · The Lancet · 2018 · 8.7K citations · Full text
Public Health, Health Sciences, Population Health Sciences +17
Jeffrey D Stanaway, Ashkan Afshin, Emmanuela Gakidou et al. · The Lancet · 2018 · 5K citations · Full text
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Thomas Unger, Claudio Borghi, Fadi J. Charchar et al. · Hypertension · 2020 · 4.1K citations · Full text